AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7574017 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (1%‐4% end‐tidal) + nitrous oxide 60% in oxygen
Number of subjects: 146
Study 7574017 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 146
Study 7574017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 146
Study 1817766 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1C antiarrhythmic drugs
Number of subjects: 0
Study 1817766 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 1817766 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatments (catheter ablation and surgery)
Number of subjects: 0
Study 1817766 — intervention group
Group type: COMPARATOR
Intervention: Class 1A antiarrhythmic drugs (disopyramide or quinidine)
Number of subjects: 0
Study 6271841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical delta 9-tetrahydrocannabinol (THC) in light mineral oil vehicles (0.05% and 0.1% solutions)
Number of subjects: 6
Study 6271841 — intervention group
Group type: COMPARATOR
Intervention: Light mineral oil vehicle
Number of subjects: 6
Study 31164169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg oral, delivered as a take-home medication for 12 weeks
Number of subjects: 180
Study 31164169 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matched to NAC, delivered as a take-home medication for 12 weeks
Number of subjects: 180
Study 31164169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 180
Study 31164169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 29801063 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI monotherapy
Number of subjects: 318
Study 29801063 — intervention group
Group type: COMPARATOR
Intervention: IAI/PDT
Number of subjects: 318
Study 27497418 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy (Agraphis nutans 5CH, Thuya Occidentalis 5CH, Kalium muriaticum 9CH, Arsenicum iodatum)
Number of subjects: 97
Study 27497418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 25252192 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV (1 mL intramuscular dose containing 40 μg HBsAg)
Number of subjects: 276
Study 25252192 — intervention group
Group type: COMPARATOR
Intervention: Licensed hepatitis B vaccine (1 mL intramuscular dose as two injections, each containing 20 μg HBsAg; total 40 μg HBsAg)
Number of subjects: 276
Study 22762143 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM+DNA vaccine
Number of subjects: 39
Study 22762143 — intervention group
Group type: COMPARATOR
Intervention: LAM monotherapy
Number of subjects: 39
Study 20054409 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) treatment with leuprolide acetate (3.75 mg) subcutaneously every 4 weeks during chemotherapy
Number of subjects: 22
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 400
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100-800 mg/day)
Number of subjects: 400
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-4 mg/day)
Number of subjects: 400
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 400
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 400
Study 17606657 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 400
Study 16053780 — intervention group
Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels measured by rapid immunofluorescence assay
Number of subjects: 117
Study 16053780 — intervention group
Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels in patients with left ventricular end-diastolic diameter (LVEDD) ≥ 60 mm
Number of subjects: 117
Study 16053780 — intervention group
Group type: EXPERIMENTAL
Intervention: B-natriuretic peptide (BNP) levels in cardiogenic dyspnea group
Number of subjects: 117
Study 16053780 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BNP with hemodynamic parameters (PCWP, MPAP, RAP)
Number of subjects: 117
Study 12115174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg infliximab every 8 weeks
Number of subjects: 428
Study 12115174 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trough serum concentrations of infliximab
Number of subjects: 428
Study 12115174 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing dosing interval from 8 weeks to 6 weeks
Number of subjects: 428
Study 11579074 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive tests (CogState) - SRT test
Number of subjects: 240
Study 11579074 — intervention group
Group type: COMPARATOR
Intervention: Non-injured players (matched controls)
Number of subjects: 240
Study 9834004 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic carbamazepine formulations
Number of subjects: 18
Study 9834004 — intervention group
Group type: COMPARATOR
Intervention: Innovator carbamazepine formulation
Number of subjects: 18
Study 7720497 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK/IL-2 plus Lycium Barbarum polysaccharides (LBP)
Number of subjects: 75
Study 7720497 — intervention group
Group type: COMPARATOR
Intervention: LAK/IL-2
Number of subjects: 75
Study 7720497 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK/IL-2 plus LBP
Number of subjects: 75
Study 2557513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium diethyldithiocarbamate (DTC)
Number of subjects: 0
Study 336378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg daily
Number of subjects: 38
Study 336378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg daily
Number of subjects: 38
Study 336378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 1200 mg daily
Number of subjects: 38
Study 336378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31729607 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal mucosal-advancement flap
Number of subjects: 150
Study 31729607 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 150
Study 31729607 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure
Number of subjects: 150
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (β1‐AR blocker)
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol + Hypoxia
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: 5050 m (high altitude)
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized Spo2
Number of subjects: 12
Study 31060374 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol + Normalized Spo2
Number of subjects: 12
Study 27533115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical amino acids and glucose supplementation (10% of feto‐placental blood volume/day) via a perinatal port system
Number of subjects: 14
Study 27533115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical amino acids and glucose supplementation
Number of subjects: 14
Study 27533115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 14
Study 26712287 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%, 1 mL/kg for caudal epidural block
Number of subjects: 90
Study 26712287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg
Number of subjects: 90
Study 26712287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg and ketamine 0.3 mg/kg
Number of subjects: 90
Study 24280465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi Qigong
Number of subjects: 206
Study 24280465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 24280465 — intervention group
Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 206
Study 21885498 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 205
Study 21885498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 19358697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 39
Study 19358697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephaquin
Number of subjects: 39
Study 19358697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquina AC Farma
Number of subjects: 39
Study 16423668 — intervention group
Group type: EXPERIMENTAL
Intervention: IV contrast with standard TVI settings
Number of subjects: 40
Study 16423668 — intervention group
Group type: EXPERIMENTAL
Intervention: IV contrast with increased TVI line density
Number of subjects: 40
Study 16423668 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no contrast)
Number of subjects: 40
Study 15578395 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-blood analysis for HCV RNA
Number of subjects: 56
Study 15578395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment with IFN (10 MU every 2 days) and ribavirin (1-1.2 g/day)
Number of subjects: 56
Study 15578395 — intervention group
Group type: COMPARATOR
Intervention: Serum and plasma specimens
Number of subjects: 56
Study 11410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-MUP analysis using mean values of MUP parameters
Number of subjects: 56
Study 11410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-MUP analysis using outliers of MUP parameters
Number of subjects: 56
Study 11410923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MUP parameters
Number of subjects: 56
Study 11410923 — intervention group
Group type: COMPARATOR
Intervention: Normative data from 64 controls
Number of subjects: 56
Study 9400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + adjuvant treatment (AT)
Number of subjects: 32
Study 9400771 — intervention group
Group type: COMPARATOR
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for fewer than 6 cycles
Number of subjects: 32
Study 9400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + AT
Number of subjects: 32
Study 9400771 — intervention group
Group type: COMPARATOR
Intervention: Chemoreduction alone
Number of subjects: 32
Study 9400771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (AT)
Number of subjects: 32
Study 7688335 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 29
Study 7688335 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 29
Study 7688335 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 29
Study 3472467 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin gel cervical ripening followed by aggressive induction of labor and delivery
Number of subjects: 302
Study 3472467 — intervention group
Group type: COMPARATOR
Intervention: Antepartum fetal testing
Number of subjects: 302
Study 30759291 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterjet dissection of the inferior hypogastric plexus (IHP)
Number of subjects: 160
Study 30759291 — intervention group
Group type: COMPARATOR
Intervention: Traditional blunt dissection of the inferior hypogastric plexus (IHP)
Number of subjects: 160
Study 30759291 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional blunt dissection)
Number of subjects: 160
Study 30759291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (waterjet and traditional dissection)
Number of subjects: 160
Study 26523442 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 Gy RBE in 5 treatments (hypofractionated)
Number of subjects: 82
Study 26523442 — intervention group
Group type: COMPARATOR
Intervention: 79.2 Gy RBE in 44 treatments (standard fractionated)
Number of subjects: 82
Study 26523442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 26773800 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation group (AG)
Number of subjects: 24
Study 26773800 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 23446076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 mcg/kg
Number of subjects: 11
Study 23446076 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 25 mg
Number of subjects: 11
Study 22845044 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 10 with ketoconazole 200 mg twice daily
Number of subjects: 20
Study 22845044 — intervention group
Group type: COMPARATOR
Intervention: BTDS 10 with placebo
Number of subjects: 20
Study 20603730 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite awareness intervention
Number of subjects: 0
Study 20603730 — intervention group
Group type: COMPARATOR
Intervention: Emotional awareness intervention
Number of subjects: 0
Study 18060958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered Pelvic Floor Distress Inventory (PFDI)
Number of subjects: 55
Study 18060958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered Pelvic Floor Impact Questionnaire (PFIQ)
Number of subjects: 55
Study 15864079 — intervention group
Group type: COMPARATOR
Intervention: Encasings (mattress, pillow and duvet)
Number of subjects: 0
Study 15864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention tailored to child's sensitization status and home environment
Number of subjects: 0
Study 12853351 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2) with carboplatin and paclitaxel
Number of subjects: 187
Study 12853351 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel without amifostine
Number of subjects: 187
Study 10618956 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine-PTC
Number of subjects: 60
Study 10618956 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine-TOF
Number of subjects: 60
Study 10618956 — intervention group
Group type: COMPARATOR
Intervention: control-PTC
Number of subjects: 60
Study 10618956 — intervention group
Group type: COMPARATOR
Intervention: control-TOF
Number of subjects: 60
Study 8701411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic transdermal E2 (50 micrograms/day for 21 days) plus medroxyprogesterone acetate (MPA) (10 mg/day from days 10 to 21)
Number of subjects: 255
Study 8701411 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal E2 (50 micrograms/day for 28 days) plus MPA (10 mg/day from days 14 to 25)
Number of subjects: 255
Study 8701411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 1906532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate (200 mg/m2/d by continuous IV infusion for 5 days)
Number of subjects: 71
Study 1906532 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (7.5 mg/kg as a 4-hour IV infusion for 5 days)
Number of subjects: 71
Study 1906532 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (7.5 mg/kg)
Number of subjects: 71
Study 1906532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 71
Study 6303061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula granulate before meals
Number of subjects: 135
Study 6303061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran before meals
Number of subjects: 135
Study 6303061 — intervention group
Group type: COMPARATOR
Intervention: Control (no fiber preparation)
Number of subjects: 135
Study 3949943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home measurement monitoring program
Number of subjects: 111
Study 29523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WPS)
Number of subjects: 100
Study 29523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation and protein supplementation (WB-EMS&P)
Number of subjects: 100
Study 29523089 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100
Study 27523653 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride
Number of subjects: 50
Study 27523653 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloids or foam dressings
Number of subjects: 50
Study 24754911 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic canola oil
Number of subjects: 170
Study 24754911 — intervention group
Group type: COMPARATOR
Intervention: Other dietary oil blends (canola oil, high oleic canola oil, flax oil, safflower oil blend, corn oil and safflower oil blend)
Number of subjects: 170
Study 23040656 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 149
Study 23040656 — intervention group
Group type: COMPARATOR
Intervention: Non-Thrust Manipulation (NTM)
Number of subjects: 149
Study 20455879 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 60 mmHg
Number of subjects: 21
Study 20455879 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 75 mmHg
Number of subjects: 21
Study 20455879 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAP of 90 mmHg
Number of subjects: 21
Study 20455879 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine titrated to target MAPs of 60, 75, and 90 mmHg
Number of subjects: 21
Study 18810296 — intervention group
Group type: EXPERIMENTAL
Intervention: HI PROT (30% of total energy intake; 1.2-1.5 g/kg/d)
Number of subjects: 24
Study 18810296 — intervention group
Group type: COMPARATOR
Intervention: LO PROT (15% of total energy intake; 0.5-0.7 g/kg/d)
Number of subjects: 24
Study 16696931 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with hazards in a simulated environment
Number of subjects: 0
Study 16696931 — intervention group
Group type: COMPARATOR
Intervention: Provision of feedback concerning performance
Number of subjects: 0
Study 12236277 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visit to primary healthcare teams
Number of subjects: 30
Study 9725505 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-D-galactosidase pellets (100 u/ml)
Number of subjects: 8
Study 9725505 — intervention group
Group type: COMPARATOR
Intervention: placebo pellets
Number of subjects: 8
Study 8017269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplane transesophageal echocardiography
Number of subjects: 80
Study 8017269 — intervention group
Group type: COMPARATOR
Intervention: Biplanar imaging
Number of subjects: 80
Study 2557219 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic heparinization
Number of subjects: 181
Study 2557219 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional heparin (high-dose)
Number of subjects: 181
Study 2557219 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional heparin (low-dose)
Number of subjects: 181
Study 2557219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 181
Study 2557219 — intervention group
Group type: EXPERIMENTAL
Intervention: Any form of heparin therapy
Number of subjects: 181
Study 1217684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg intramuscularly
Number of subjects: 2
Study 1217684 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 60 mg intramuscularly
Number of subjects: 2
Study 1217684 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 60 mg intramuscularly with Pentazocine 30 mg
Number of subjects: 2
Study 31775535 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium valproate
Number of subjects: 175
Study 31775535 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 175
Study 28863886 — intervention group
Group type: COMPARATOR
Intervention: Selective neck dissection (group I)
Number of subjects: 20
Study 28863886 — intervention group
Group type: EXPERIMENTAL
Intervention: Superselective neck dissection (group II)
Number of subjects: 20
Study 27923343 — intervention group
Group type: EXPERIMENTAL
Intervention: Home tele-management programme delivered by a multidisciplinary health team, involving nurse-tutor telephone support and tele-exercise, followed for 6 months after hospital discharge.
Number of subjects: 0
Study 27923343 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 0
Study 24323569 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 300
Study 24323569 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of others smoking
Number of subjects: 300
Study 24323569 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect
Number of subjects: 300
Study 24323569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three triggers (alcohol consumption, presence of others smoking, negative affect)
Number of subjects: 300
Study 22703794 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 100
Study 22703794 — intervention group
Group type: COMPARATOR
Intervention: Collagenase ointment (CO)
Number of subjects: 100
Study 20188280 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage method
Number of subjects: 50
Study 20188280 — intervention group
Group type: COMPARATOR
Intervention: 1-stage method
Number of subjects: 50
Study 17710398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg single dose on day +5)
Number of subjects: 44
Study 17710398 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 microg kg(‐1) day(‐1) starting on day +5)
Number of subjects: 44
Study 17710398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 44
Study 17710398 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 44
Study 15516347 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 200
Study 15516347 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI monitoring
Number of subjects: 200
Study 15516347 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 200